Join our daily newsletter At The Bell to receive exclusive market insights
- Sienna Cancer Diagnostics is up more than 20 per cent today after announcing a new CEO for the company
- Carl Stubbings will replace Matthew Hoskin effective immediately
- Carl was previously non-executive Director of Sienna since 2011
- Shares in Sienna are up 22.2 per cent, trading for 5.5 cents apiece
Sienna Cancer Diagnostics is up more than 20 per cent after appointing Carl Stubbings as the new CEO, effective immediately.
Carl will be transferring from his role as Non-Executive Director to replace current CEO, Matthew Hoskin.
Carl is a highly experienced senior leader in the biotechnology and diagnostics industry with a focus on commercialisation, sales, marketing and business development.
He has been the Non-Executive Director of Sienna since 2011 and prior to that, his most recent role was CEO at BCAL – a private company that is developing a breast cancer diagnostic.
Based in the U.S. for 13 years, Carl served as Senior Vice President, for Panbio USA and Vice-President of Sales and Marketing for Focus Diagnostics.
In 2012, Carl moved back to Australia where he was quickly appointed Chief Business Officer at Benitec Biopharma.
Recently, he has been assisting several Australian biotech companies with their commercialisation strategies. These companies include Minomic, an Immune Oncology company with prostate cancer tests, and Biotron, a listed company that is developing and commercialising anti-viral small molecule therapies.
Carl was previously Non-Executive Director of Analytica Medical until November 2017.
Matthew joined Sienna in early 2014 and brought his experience in leading and growing medtech companies both locally and internationally.
With over 20 years’ experience in leading businesses in the medtech and healthcare sectors, he played a key role in developing and turning around the companies he worked for.
At Sienna, Matthew’s efforts were focused on company growth and achieving profitability through the delivery of high-quality products that addressed previously unmet market needs.
His interest in cancer diagnostics has seen him work with a number of multi-national companies, that specialise in antibodies and reagent detection systems, automated IHC/ICC strainers, tissue processors and oncology pharmaceuticals.
Sienna Chairman Geoff Cumming is thankful for all the work Matthew has done for the company.
“On behalf of the Board and the team at Sienna, I would like to sincerely thank Matthew for his contribution to and leadership of the company over the past five years, first as Chief Operating Officer and more recently as Chief Executive Officer,” he said.
In light of this news Sienna shares are up 22.2 per cent, trading for 5.5 cents apiece at 12:46 pm AEDT.
